Skip to main content

Advertisement

SpringerLink
Log in

Benefit Corporation: a path to affordable gene therapies?

  • Comment
  • Published:

From Nature Medicine

View current issue Submit your manuscript

With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. High, K. A. & Roncarolo, M. G. N. Engl. J. Med. 381, 455–464 (2019).

    Article  Google Scholar 

  2. Marsden G., Towse, A., Pearson, S. D., Dreitlin, B. & Henshall, C. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value https://icer-review.org/material/white-paper-gene-therapy (2017).

  3. Bach, P. B. ‘Anchoring’ was at work in setting the price of Novartis’ new gene therapy. STAT https://www.statnews.com/2019/06/04/anchoring-price-zolgensma (2019).

  4. Brody, B. The Hastings Center Report 26, 5–11 (1996).

    Article  CAS  Google Scholar 

  5. World Health Organization. Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products [footnote]. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf (2019).

  6. Cummings, B. Columbia Law Rev. 112, 578–627 (2012).

    Google Scholar 

  7. Business Roundtable. Our Commitment. https://opportunity.businessroundtable.org/ourcommitment (2019).

Download references

Author information

Authors and Affiliations

  1. Collège de France, Assistance Publique des Hôpitaux de Paris, Hôpital Necker Enfants Malades, Unité d’Immunologie-Hématologie Pédiatrique, and Imagine Institute, INSERM UMR 1163, Paris, France

    Alain Fischer

  2. Ecares, Solvay Brussels School of Economics and Management, Université libre de Bruxelles, Brussels, Belgium

    Mathias Dewatripont

  3. I3h Institute, Université libre de Bruxelles, Brussels, Belgium

    Mathias Dewatripont & Michel Goldman

Authors
  1. Alain Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathias Dewatripont
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alain Fischer or Michel Goldman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fischer, A., Dewatripont, M. & Goldman, M. Benefit Corporation: a path to affordable gene therapies?. Nat Med 25, 1813–1814 (2019). https://doi.org/10.1038/s41591-019-0676-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0676-z

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation